Tests elironrasib combinations in lung cancer with a RAS G12C mutation
Tests elironrasib with other cancer drugs in adults with RAS G12C-mutated lung cancer.
Key facts
- Who runs it
- Revolution Medicines Inc.
- Where
- Berlin, Cologne, Dresden, Frankfurt Am Main, Heidelberg, Immenhausen, and Moers, GermanySee the 7 sitesAlso in 4 other countries, 34 sites
- Trial code
- EU 2023-509571-16-00
- NCT06162221
- Registry title
- Study of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 330 people, planned
- Started
- 17 Jul 2024
- Expected to end
- 30 Oct 2027
- Type of study
- Interventional
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a solid tumor that has a RAS G12C change, including non-small cell lung cancer. People must have had earlier cancer treatment or be unable to tolerate regular treatments.
- Age
- 18 years or older, or the legal age of consent.
- Sex
- All sexes can join.
- Disease stage
- Solid tumor with RAS G12C and at least one tumor lesion that can be measured.
- Earlier treatment
- Must have had prior cancer treatment or be unable to tolerate regular treatments. Cannot have taken targeted therapy for a KRAS mutation before.
- Biomarker or test result
- RAS G12C mutation.
Main reasons for not taking part
- Primary brain or spinal cord tumor
- Gastrointestinal problems that may affect absorption of elironrasib
- Any major surgery in the last 4 weeks
- Earlier targeted therapy for a KRAS mutation
- Other medical conditions, medicines, foods or treatments that may interfere with the study drugs
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- ≥ Patients that are at least 18 years old, or legal age of consent. 2. Patients that have solid tumor with RAS-G12C. 3. Patients that have received prior cancer treatment or are not able to tolerate regular treatments. 4. Patients that have at least one tumor lesion (an area of abnormal tissue) that can be measured. 5. Patients that have adequate organ function (bone marrow, liver, kidney)
Who cannot take part
- Participants that have primary brain and spinal cord tumor. 2. Participants thathave gastrointestinal problems that may affect absorption of elironrasib. 3. Participants thathad any major surgery in the last 4 weeks. 4. Participants thathave any other medical condition that may interfere with the study drugs. 5. Participants that have previously taken targeted therapy for KRAS mutation. 6. Participants that need other medicines, eat foods, or receive treatments that may interfere with the study drugs
Where in Germany
Also in 4 other countries, 34 sites
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- University Hospital Cologne AöRCologne, GermanyTaking people
- Technische Universitaet DresdenDresden, GermanyTaking people
- Goethe University FrankfurtFrankfurt Am Main, GermanyTaking people
- Thoraxklinik Heidelberg gGmbHHeidelberg, GermanyTaking people
- Lungenfachklinik ImmenhausenImmenhausen, GermanyTaking people
- Stiftung Krankenhaus Bethanien Fuer Die Grafschaft MoersMoers, GermanyTaking people
About the trial
What the trial wants to find out
To evaluate the safety and tolerability of elironrasib in combination with pembrolizumab, with or without daraxonrasib, with or without chemotherapy, in patients with advanced RAS G12C-mutated solid tumors To define the RP2DS for elironrasib in combination with pembrolizumab, with or without daraxonrasib, with or without chemotherapy, in patients with advanced RAS G12C-mutated NSCLC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Study of Elironrasib (RMC-6291), With or Without Daraxonrasib (RMC-6236), in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
- Plain-language title
- Tests elironrasib combinations in lung cancer with a RAS G12C mutationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 9 October 2026